|
Univariate analyses of clinicopathological factors and molecular markers |
||||||
| Number |
3 yr DFS |
P |
3 yr OS |
P |
||
|
|
||||||
| Tumor size |
< 5 cm ≥5 cm |
121 30 |
78.6% 42.3% |
0.038 |
92.1% 91.1% |
0.952 |
| Number of lymph nodes |
4–9 ≥10 |
79 72 |
89.8% 52.7% |
< 0.001 |
100% 83.7% |
0.001 |
| Surgery |
MRM BCS |
120 31 |
70.0% 79.0% |
0.808 |
90.9% 96.3% |
0.953 |
| Histology |
Ductal Others |
138 13 |
71.1% 76.9% |
0.461 |
91.0% 100.0% |
0.323 |
| Histologic grade |
I, II III |
65 76 |
74.7% 69.5% |
0.160 |
98.4% 84.3% |
0.043 |
| Endolymphatic tumor emboli |
absent present |
5 116 |
55.6% 71.7% |
0.459 |
100% 91.6% |
0.490 |
| Close RM |
≤2 mm > 2 mm |
5 146 |
70.8% 80.0% |
0.590 |
91.5% 100% |
0.475 |
| ER |
(-) (+) |
68 83 |
64.9% 77.2% |
0.013 |
83.4% 100% |
0.006 |
| PR |
(-) (+) |
92 59 |
68.3% 76.2% |
0.136 |
87.1% 100% |
0.121 |
| p53 |
≤25% >25% |
105 46 |
75.5% 62.1% |
0.032 |
93.8% 87.8% |
0.213 |
| bcl-2 |
(-) (+) |
59 92 |
62.0% 77.6% |
0.002 |
83.9% 97.4% |
0.009 |
| c-erbB2 |
(-) to (2+) (3+) |
121 30 |
74.3% 60.6% |
0.112 |
96.3% 79.6% |
0.050 |
| Ki-67 |
< 5% ≥5% |
94 56 |
85.6% 61.8% |
0.146 |
91.0% 92.4% |
0.631 |
Lee et al. BMC Cancer 2007 7:63 doi:10.1186/1471-2407-7-63 |
||||||